ORIC

Oric Pharmaceuticals Inc

ORIC.US oricpharma.com + Research + Basket
CIK 0001796280
Employees 111
Phone 650 388 5600
Fiscal year end December
IPO Apr 24, 2020
Address 240 E. Grand Ave, South San Francisco, CA, United States, 94080
9.30
+0.30 (+3.33%)
USD · NASDAQ
52-week range
7.23
14.68
Trading at 28% of the 52-week range
Market Cap
932.87M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.68
Div. Yield
N/A
% Institutions
123.41%
% Insiders
1.59%

1 Year

-30.8%

3 Year

+46.0%

10 Year

-63.9%
Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Actions

Add an action for ORIC.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Richard A. Heyman Ph.D. Founder, Independent Chairman & Member of Scientific Advisory Board 1957
Dr. Jacob M. Chacko M.B.A., M.D. President, CEO & Director 1979
Mr. Dominic G. Piscitelli CPA, M.B.A. Chief Financial Officer 1975
Dr. Pratik S. Multani M.D., M.S. Chief Medical Officer 1967
Dr. Charles L. Sawyers B.A., M.D., Ph.D. Founder & Member of Scientific Advisory Board 1959
Dr. Scott W. Lowe Ph.D. Founder & Member of Scientific Advisory Board NA
Dr. Kevin Brodbeck Ph.D. Chief Technical Officer NA
Dr. Lori Sickels Friedman Ph.D. Chief Scientific Officer 1965
Mr. Daniel Iazzetti VP & Head of People NA
Dr. Edna Chow Maneval Ph.D. Executive Vice President of Clinical Development 1961

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Feb 24, 2026 Dominic Piscitelli N/A Sale 52.00K $13.51 $702.52K SEC
Dec 16, 2025 Dominic Piscitelli N/A Sale 10.72K $9.06 $97.12K SEC
Dec 16, 2025 Jacob Chacko N/A Sale 33.37K $9.06 $302.37K SEC
Dec 16, 2025 Pratik S Multani N/A Sale 10.72K $9.06 $97.12K SEC
Oct 06, 2025 Dominic Piscitelli N/A Sale 11.00K $14.52 $159.72K SEC
Oct 06, 2025 Jacob Chacko N/A Sale 37.46K $12.32 $461.52K SEC
Oct 01, 2025 Jacob Chacko N/A Sale 53.00K $12.05 $638.66K SEC
Sep 30, 2025 Jacob Chacko N/A Sale 34.54K $12.01 $414.80K SEC
Sep 22, 2025 Jacob Chacko N/A Sale 125.00K $10.80 $1.35M SEC
Jun 24, 2025 Dominic Piscitelli N/A Sale 32.47K $10.50 $340.89K SEC
Jun 23, 2025 Angie You N/A Purchase 1.40K $9.43 $13.23K SEC
Jun 23, 2025 Dominic Piscitelli N/A Sale 1.03K $10.00 $10.34K SEC
Jun 20, 2025 Angie You N/A Purchase 26.60K $9.39 $249.75K SEC
Jun 12, 2025 Dominic Piscitelli N/A Sale 300.00 $10.00 $3.00K SEC
Jun 11, 2025 Dominic Piscitelli N/A Sale 2.98K $10.01 $29.79K SEC
Jun 10, 2025 Dominic Piscitelli N/A Sale 324.00 $10.00 $3.24K SEC
Jun 09, 2025 Dominic Piscitelli N/A Sale 300.00 $10.00 $3.00K SEC
Jun 06, 2025 Dominic Piscitelli N/A Sale 2.60K $10.01 $26.03K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Nextech Invest, Ltd. 7.16M Jun 30, 2026 6.91% $3.68 0.00%
BlackRock Inc 6.82M Jun 30, 2026 6.58% $0.00 14.03%
EcoR1 Capital, LLC 6.73M Jun 30, 2026 6.49% $3.54 0.00%
T. Rowe Price Associates, Inc. 6.62M Jun 30, 2026 6.38% $0.01 22.83%
Viking Global Investors LP 5.13M Jun 30, 2026 4.95% $0.16 -11.98%
State Street Corp 4.89M Jun 30, 2026 4.72% $0.00 32.19%
SR ONE CAPITAL MANAGEMENT, LP 4.62M Jun 30, 2026 4.45% $4.81 2.23%
VR Adviser, LLC 4.32M Jun 30, 2026 4.17% $1.42 0.00%
NEA Management Company, LLC 4.12M Jun 30, 2026 3.97% $2.81 0.00%
Vanguard Capital Management, LLC 3.95M Jun 30, 2026 3.81% $0.00 7.16%
AIHC Capital Management Limited 3.83M Jun 30, 2026 3.69% $39.77 55.66%
Alkeon Capital Management, LLC 3.74M Jun 30, 2026 3.61% $0.05 -16.98%
Column Group LLC 3.54M Jun 30, 2026 3.42% $43.53 0.00%
Siren, L.L.C. 3.00M Jun 30, 2026 2.89% $0.66 0.00%
FMR Inc 2.64M Jun 30, 2026 2.54% $0.00 8.27%
Citadel Advisors Llc 2.60M Jun 30, 2026 2.50% $0.00 7.12%
The Goldman Sachs Group Inc 2.45M Jun 30, 2026 2.37% $0.00 66.14%
Geode Capital Management, LLC 2.09M Jun 30, 2026 2.02% $0.00 13.67%
First Turn Management LLC 2.02M Jun 30, 2026 1.95% $2.34 0.00%
Orbimed Advisors LLC 2.02M Jun 30, 2026 1.94% $0.40 -25.20%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 2.96M 2.86% ▲ 0.00% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 2.43M 2.35% ▼ 1.88% Sep 30, 2026
3 iShares Russell 2000 ETF 1.94M 1.87% ▼ 1.14% Sep 30, 2026
4 ACAP Strategic A 1.85M 1.79% ▼ 16.87% Jun 30, 2026
5 Franklin Biotechnology Discv A(acc)USD 1.22M 1.18% ▲ 0.00% Sep 30, 2026
6 T. Rowe Price Health Sciences 1.20M 1.15% ▲ 0.00% Sep 30, 2026
7 Eventide Healthcare & Life Sciences I 951.43K 0.92% ▲ 0.00% Jun 30, 2026
8 T. Rowe Price New Horizons 903.29K 0.87% ▼ 11.03% Sep 30, 2026
9 Fidelity Small Cap Index 817.88K 0.79% ▲ 0.80% Jul 31, 2026
10 T. Rowe Price Integrated US Sm Gr Eq 787.50K 0.76% ▼ 37.56% Sep 30, 2026

Financial Highlights

▼
Market Cap: $932.87M
EBITDA: $-155.00M
Book Value: $3.68
Earnings/Share: $-1.32
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -25.97%
ROE (TTM): -39.80%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $666.77M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 103.65M
Shares Float: 88.69M
% Insiders: 1.59%
% Institutions: 123.41%
Short % Float: 15.91%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.22M
Gross Profit
subtotal
$-1.22M
SG&A
adjust
$-33.19M
R&D
adjust
$-109.82M
Operating Income
subtotal
$-143.00M
Other / Non-Operating Items
adjust
$13.54M
Net Income
subtotal
$-129.47M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ORIC.US!